The Medical Letter on Drugs and Therapeutics
Perampanel (Fycompa) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Perampanel (per am' pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.1

MECHANISM OF ACTION — AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are a subtype of glutamate receptors. Perampanel is a noncompetitive antagonist of AMPA receptors on post-synaptic neurons. In vitro, it inhibits AMPA-dependent increases in intracellular calcium, but the mechanism by which it reduces seizure activity is unclear.2

CLINICAL STUDIES — Approval of perampanel was based on the results of 3 randomized, double-blind, placebo-controlled trials in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Perampanel (Fycompa) for Epilepsy
Article code: 1435a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian